top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)

AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.

Click here now for the full details of this stock that’s set to rocket in the AI revolution…

Elizabeth Crowley net worth and biography

Elizabeth Crowley Biography and Net Worth

VP of Celldex Therapeutics

Elizabeth Crowley is Senior Vice President, Chief Product Development Officer of Celldex. Ms. Crowley joined Celldex in 2009 as Vice President, Clinical Development. Prior to that, she held several senior level roles at CuraGen Corporation, most recently serving as the Vice President of Development Operations, responsible for strategic and operational development activities of the oncology and oncology supportive care portfolio, regulatory affairs, clinical operations and data management. Ms. Crowley started her career at Bayer Corporation in 1992, holding various positions providing leadership of clinical research and project management prior to completing her tenure there as the Director of Global Study Audit Management, assuring the highest standards for program execution. Ms. Crowley received her BS in Chemistry with a concentration in Business from Boston College.

How do I contact Elizabeth Crowley?: The corporate mailing address for Ms. Crowley and other Celldex Therapeutics executives is 53 FRONTAGE ROAD SUITE 220, HAMPTON NJ, 08827. Celldex Therapeutics can also be reached via phone at (908) 454-7120 and via email at [email protected]. Learn More on Elizabeth Crowley's contact information.
Has Elizabeth Crowley been buying or selling shares of Celldex Therapeutics?: Elizabeth Crowley has not been actively trading shares of Celldex Therapeutics during the past quarter. Most recently, Elizabeth Crowley sold 4,000 shares of the business's stock in a transaction on Wednesday, December 8th. The shares were sold at an average price of $40.00, for a transaction totalling $160,000.00. Learn More on Elizabeth Crowley's trading history.
Who are Celldex Therapeutics' active insiders?: Celldex Therapeutics' insider roster includes Sarah Cavanaugh (SVP), Elizabeth Crowley (VP), Freddy Jimenez (SVP), Samuel Martin (CFO), Anthonly Marucci (President & CEO), and Diane Young (SVP). Learn More on Celldex Therapeutics' active insiders.

Elizabeth Crowley Insider Trading History at Celldex Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
12/8/2021	Sell	4,000	$40.00	$160,000.00

Elizabeth Crowley Buying and Selling Activity at Celldex Therapeutics

Celldex Therapeutics Company Overview

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Today's Range

Now: $37.02

$36.96

$37.90

50 Day Range

MA: $42.12

$36.80

$51.88

2 Week Range

Now: $37.02

$22.11

$53.18

Volume

394,653 shs

Average Volume

881,711 shs

Market Capitalization

$2.07 billion

P/E Ratio

N/A

Dividend Yield